Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rajiv Tayal

Interventional Cardiology Fredericksburg, VA Medical Doctor

NPI 1134457898 CMS profile 51874

9530 Cosner Dr, Suite 200, Fredericksburg, VA 22408

Open in the dashboard

General payments

$983,513

1,372 records reported · program years 2019–2025

Research payments

$342

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$984,632 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Rajiv Tayal of Fredericksburg, VA is reported in the CMS Open Payments database as having received $983,513 across 1,372 general payments and $342 in research payments paid to them. Separately, studies naming them as principal investigator received $984,632 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $146,165 245
2024 General $170,150 245
2023 General $120,157 128
2023 Research $342 1
2022 General $116,307 189
2021 General $46,089 79
2020 General $108,352 95
2019 General $276,294 391

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rajiv Tayal
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Rajiv Tayal were reported at $146,165. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Rajiv Tayal Interventional Cardiology median Middle half National median
2019 $276,294 $1,097 $329–$3,048 $163
2020 $108,352 $473 $161–$1,480 $114
2021 $46,089 $677 $233–$1,827 $132
2022 $116,307 $978 $333–$2,724 $149
2023 $120,157 $1,136 $382–$2,986 $160
2024 $170,150 $1,181 $395–$3,326 $164
2025 $146,165 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abiomed $554,619 495 payments
  2. Edwards Lifesciences Corporation $161,901 332 payments
  3. Medtronic, Inc. $150,991 236 payments
  4. Shockwave Medical, Inc $89,470 56 payments
  5. Abbott Laboratories $10,224 61 payments
  6. Cardiovascular Systems Inc. $3,124 31 payments
  7. Magenta Medical Inc $3,000 2 payments
  8. Boston Scientific Corporation $2,700 27 payments
  9. Medtronic Vascular, Inc. $1,802 16 payments
  10. Opsens Inc. $1,553 9 payments
  11. Other $4,129 107 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $455,144 113 payments
  2. Travel and Lodging $204,794 460 payments
  3. Consulting Fee $172,475 45 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $83,425 27 payments
  5. Food and Beverage $41,544 713 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $26,075 12 payments
  7. Entertainment $39 1 payment
  8. Education $17 1 payment
Products named General payments · program years 2019–2025
  1. Impella $512,338 445 payments
  2. Edwards SAPIEN 3 Transcatheter Heart Valve $105,412 166 payments
  3. COREVALVE EVOLUT R $51,171 99 payments
  4. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $38,003 37 payments
  5. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Lithoplasty $33,724 22 payments
  6. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Cardiology $29,089 15 payments
  7. Vascular Lithotripsy $23,411 12 payments
  8. FFRANGIO $23,109 16 payments
  9. SYMPLICITY G3 $8,031 15 payments
  10. Perclose ProGlide suture mediated closure system $3,548 7 payments
  11. Other $32,905 362 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Abiomed $342 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

761

Median for Interventional Cardiology: 2,236

Drug cost

$147,962

Median for Interventional Cardiology: $380,412

Branded share of claims

33.6%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 51 $61,879
Brilinta Ticagrelor Brand 25 $30,374
Entresto Sacubitril/Valsartan Brand 15 $17,908
Praluent Pen Alirocumab Brand 18 $15,961
Repatha Sureclick Evolocumab Brand 17 $13,589
Metoprolol Succinate Generic 120 $1,663
Clopidogrel Clopidogrel Bisulfate Brand 96 $1,337
Rosuvastatin Calcium Generic 66 $1,169
Atorvastatin Calcium Generic 103 $925
Amlodipine Besylate Generic 45 $501

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$264,142

Medicare's payments for the services billed

Medicare patients

483

Average age 79

Services billed

2,142

183 women, 300 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Arthritis 58%
Heart failure 45%
Diabetes 41%
Atrial fibrillation 40%
Chronic kidney disease 37%
Cancer 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
$67 17 —
Arcalyst
$31 — —
LEQVIO
$24 — —
Wegovy
$20 — —
VYNDAQEL
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

1,373 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record